Tuesday, 31 Mar 2020

You are here

Tacrolimus Tops Other DMARDs as Induction Therapy for Lupus Nephritis

Metanalysis of nine clinical trials and 972 lupus patients examined the comparative efficacy of tacrolimus, mycophenolate (MMF) and cyclophosphamide (CYC) as induction therapy for lupus nephritis. Pairwise comparisons were performed, including 11 direct comparisons (Citation source http://buff.ly/1U1wchB).

The response rate with tacrolimus was significantly higher than with CYC (OR 2.35, 95% CI 1.03-5.45). The overall response rate was higher, though not statistically significantly so, with MMF compared with CYC (OR 1.45, 95% CI 0.96-2.42). Tacrolimus was most efficacious as induction treatment for patients with lupus nephritis, and had the highest probability of decreasing the risk of serious infections. Higher remission rates combined with a more favorable safety profile suggest that MMF is superior to CYC as induction treatment in these patients.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

In Lupus, Keep BP Below 130/80

Blood pressure should be maintained at a level below 130/80 mm Hg in all patients with lupus to lessen their likelihood of atherosclerotic vascular events, Canadian researchers asserted.

In Vasculitis, Beware of Infection

Risks of infection were strikingly high among patients with antineutrophil cytoplasmic antibody-associated (ANCA) vasculitis, which may relate to both the disease and its treatment, Scottish researchers found.

Malignancies with Giant Cell Arteritis

The Journal of Rheumatology reports the findings of a Swedish population-based cohort study of biopsy-proven giant cell arteritis (GCA) patients showing that the overall risk for cancer was not increased; yet there appears to be an increased risk for leukemia and a decreased risk for breast and upper gastrointestinal tract cancers.   

Hospitalized GPA - Higher morbidity, Mortality and Cost

Rheumatology reports on a study of patients with granulomatosis with polyangiitis (GPA) showing worse outcomes and higher costs when hospitalized with GPA.

GPA patients were identified from the Nationwide Inpatient Sample (NIS) and were compared to those without GPA with regard to demographics, procedures, length of stay, mortality, morbidity and total hospitalization charges (between 2005–2014).

Don't Blame the Weather in Sjogren's

Seasonal variations in symptoms -- commonly reported by patients with rheumatic diseases -- were not observed in a large cohort of patients with primary Sjogren's syndrome, French investigators found.